Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-11-03
Ethical does not pass the values gate
Price27.60 USD
Fair value28.16Our model only; only one analyst covers it, too few to cross-check it.
Ethical score70.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation26.55+4.0% to today ✓Markdown gives way to Accumulation after a 9% rise in 9 days
2026-10-02Read Markdown24.27+13.7% to today Distribution gives way to Markdown after a 5% slide in 3 weeks
2026-09-12Read Distribution25.66+7.6% to today Markup gives way to Distribution after a 16% slide in 10 weeks
2026-07-02Read Markup30.41-9.2% to today First review on file: Markup with results news in the headlines
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ryerson Holding Corporation holds its Accumulation at $27.60. The statistical read favours the buyers, held for 16 days.
As held on the ledger · 2026-11-06
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 16 days
Price at the screen
$27.60
Valuation
N/A trailing · 9.63 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.50
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.92%
Below 33%
Interest-bearing debt is 33.9% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
20.28%
Below 49%
Money owed to the company is 20.3% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Ryerson's business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RYZ's ethical verdict changes
Today RYZ does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 6% discount to our $28.16 fair value, 87.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 2.0% discount to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Where our models see it going: fair-value estimate $28.16, with a range of $28.16 to $32.39, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cyclical Metals Business Risks Earnings Peak Trap
Picture a steel yard in the Midwest where orders surge when factories rebuild and vanish when rates climb. Ryerson shows 38% revenue growth yet posts a negative 1% profit margin and minus 4% return on equity, which tells us the top line is riding a cycle rather than building durable earnings.
The forward multiple sits at 12.6 times, which looks cheap until you remember this is a classic cyclical value trap where peak earnings produce low multiples that later collapse. Our fair value sits 18% below the current price and the opportunity rating is none, so the numbers do not support ownership even though the ethical screen clears.
One analyst rates it a hold with a 29 dollar target, but the unknown moat and exposure to metal price swings keep the risk squarely on earnings volatility rather than any structural edge. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RYZ trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$32.01+14.1%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29.
2026-10-28Accumulation$28.05+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$28.05+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$28.05+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$28.05+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$28.05+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$28.05+5.8%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$26.50+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$26.50+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$26.50-0.2%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it hold, with a mean price target of $29.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.